All Fulcrum Publications

March 16, 2022

Annualized Rates of Change from A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of Losmapimod in Subjects with FSHD: ReDUX4

Rabi Tawil, MD

March 16, 2022

Reachable Workspace to Evaluate Efficacy of Losmapimod in Subjects with FSHD in Two Phase 2 Studies

Joost Kools, Nicol Voermans, Karlien Mul, Baziel van Engelen, Michelle L. Mellion, John Jiang, Jennifer Shoskes, Kelly Marshall, David Jackson, Yuxi Zhao, Anil Tarachandani, Joanita Figueredo, Damien Eggenspieler

March 16, 2022

Feasibility of Measuring Functional Performance of FSHD Patients Using Wearable Sensors to Quantify Physical Activity

Joost Kools, Nicol Voermans, Karlien Mul, Baziel van Engelen, Michelle L. Mellion, John Jiang, Jennifer Shoskes, Kelly Marshall, David Jackson, Yuxi Zhao, Anil Tarachandani, Joanita Figueredo Damien Eggenspieler

March 16, 2022

An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1

Joost Kools, Nicol Voermans, Karlien Mul, Lucienne Ronco, John Jiang, Jennifer Shoskes, Kelly Marshall, Diego Cadavid, Michelle L. Mellion, Baziel van Engelen

December 11, 2021

In vivo characterization of EED inhibitors, novel small molecule fetal hemoglobin inducers for sickle cell disease

B. Stuart, P. Bruno, K. Xie, I. Efremov, S. Silver, L. Thompson, C. Moxham

December 1, 2021

Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement

Mellion ML, L Ronco, CL Berends, L Pagan, S Brooks, MJ van Esdonk, EMJ van Brummelen, A Odueyungbo, LA Thompson, M Hage, UA Badrising, S Raines, WG Tracewell, B van Engelen, D Cadavid, GJ Groeneveld

September 23, 2021

An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1

Joost Kools, Nicol Voermans, KarlienMul, Lucienne Ronco, John Jiang, Jennifer Shoskes, Kelly Marshall, Diego Cadavid, Michelle L. Mellion, Baziel van Engelen

September 23, 2021

Quantitative Muscle Analysis in FSHD Using Whole-Body MRI: Composite Muscle Measurements for Cross-Sectional Analysis

Per Widholm, Markus Karlsson, André Ahlgren, Olof Dahlqvist-Leinhard, Rabi Tawil, Kathryn Wagner, Jeffrey Statland, Leo Wang, Perry Shieh, Baziel Van Engelen, Diego Cadavid, Lucienne Ronco, Adefowope Odueyungbo, Jay Han, Maya Hatch, Michelle L. Mellion

September 23, 2021

Whole Body MRI Quantitative muscle analysis to evaluate Efficacy of Losmapimod in a Phase 2 Placebo-Controlled Study in Subjects with FSHD (ReDUX4): ReDUX4 (NCT04003974)

Rabi Tawil, Kathryn Wagner, Jeffrey Statland, Leo Wang, Angela Genge, Sabrina Sacconi, Hanns Lochmüller, David Reyes Leiva, Jordi Diaz-Manera, Jorge Alonso-Perez, Nuria Muelas, Juan J. Vilchez, Alan Pestronk, Summer Gibson, Namita A. Goyal, Johanna Hamel, Lawrence Hayward, Nicholas Johnson, Samantha LoRusso, Miriam Freimer, Perry B. Shieh, Sankarasubramoney H. Subramony, Doris Leung, Baziel van Engelen, Joost Kools, Olof Dahlqvist, Per Widholm, John Jiang, Adefowope Odueyungbo, William Tracewell, Alisa Rahilly, Alejandro Rojas, Anthony Accorsi, Steve Mennen, Lucienne Ronco, Diego Cadavid, Christopher M. Moxham, Christopher Morabito, Robert Gould, Michelle L. Mellion

April 9, 2021

Discovery of Clinical Candidate FTX 6058: A Potent, Orally Bioavailable Upregulator of Fetal Hemoglobin for Treatment of Sickle Cell Disease

Ivan V. Efremov, Kingsley Kofi Appiah, Angela Cacace, Yanfei Dong, Shawn D. Johnstone, Steven Kazmirski, Qingyi Li, Christopher Moxham, Peter Rahl, Mark Roth, Billy Stuart, Lorin A. Thompson, III, Owen B. Wallace, Keqiang Xie, Feng Zhou